CutisPharma Appoints Neal Muni, MD, MSPH as President
WILMINGTON, Mass., July 15, 2014
WILMINGTON, Mass., July 15, 2014 /PRNewswire/ --CutisPharma announced today
that it has appointed Neal Muni, MD, MSPH as President and member of the Board
of Directors.Dr. Muni will assume responsibility for overseeing the company's
commercial operations and guiding development strategy for its product
"We are pleased that Neal has joined our team to take our company to the next
level of growth and continue our leading position as an innovator in
pharmaceutical compounding," said Dr. Indu Muni, Chief Executive Officer of
CutisPharma."Neal's experience in the pharmaceutical industry, life science
consulting, FDA and his background as a practicing physician bring a unique
and highly effective skill set to develop our long-term strategic vision and
build out the operational infrastructure to meet our goals."
"I am thrilled to be joining CutisPharma at this exciting stage of the
company's history and leading its transformation into a fully-integrated
industry leader in the pharmaceutical compounding market," said Neal Muni,
President of CutisPharma."We have a great opportunity to address the needs of
patients by continuing to bring innovation to this niche sector of the
industry and to significantly grow our business."
Prior to joining CutisPharma, Dr. Muni served as the Executive Director of New
Product Planning at Sunovion Pharmaceuticals, a US subsidiary of Dainippon
Sumitomo Pharma, where he led the Corporate Strategy group's commercial
assessment of the company's R&D portfolio and corporate M&A and licensing
activities. Dr. Muni also currently maintains staff appointments with the
Department of Medicine at Brigham and Women's Hospital, where he practices as
an internist with the Brigham Hospitalist Service, and Harvard Medical School,
appointed as an Instructor of Medicine.Prior to joining Sunovion, Dr. Muni
was an engagement manager in the strategic advisory practice of Leerink Swann,
LLC, a Boston-based health-care boutique investment bank. Prior to that, Dr.
Muni was a Medical Officer in the Division of Cardiovascular Devices at the
FDA, serving as the lead medical reviewer for coronary drug eluting stent
technologies. Dr. Muni completed his residency training in internal medicine
at the Brigham and Women's Hospital. He received his M.D. as well as Master of
Science in Public Health, specializing in biostatistics, from the Tulane
School of Medicine, and a B.A. in Business Economics and B.Sc. in Biochemistry
from Brown University.
CutisPharma, Inc. based in Wilmington, MA, is a privately held, specialty
pharmaceutical company focusing on the development and commercialization of
value-added proprietary drug products and technologies in the prescription
compounding sector of the pharmaceutical industry. Product line and
development efforts are focused on providing optimized, more efficient
alternatives for the preparation of the nearly 20 million currently compounded
prescriptions, by offering FIRST® Unit-of-Use Prescription Compounding Kits.
Use of these branded compounding kits will be beneficial to all triad
participants, namely physicians, pharmacists, and patients. Four U.S. patents
have been issued to the Company with additional patents pending, including
"Composition and Method for Vancomycin Oral Liquid".
For more information please visit our website at www.cutispharma.com
SOURCE CutisPharma, Inc.
Contact: James Nagle, V.P. Business Development, CutisPharma, Inc.,
Press spacebar to pause and continue. Press esc to stop.